According to Jefferies analysts, Bayer is facing challenges on multiple fronts that are pushing the need to explore strategic options. The halt of a late-stage clinical trial for experimental cardiovascular drug asundexian has pushed financial risk to the edge. Additionally, falling share prices have increased the sensitivity of the company to rising provisions and potential trial losses in a legal battle over its Roundup weedkiller. This suggests that Bayer might need to sell assets and scrap dividends in order to buy time, but this may not be enough for large-scale investments needed in its pharmaceutical business, according to Jefferies. As a result, Jefferies has cut its recommendation on the stock from buy to hold. Despite Monday’s heavy losses, shares trade 0.3% higher following the news. (adria.calatayud@dowjones.com) Copyright ©2023 Dow Jones & Company, Inc. All Rights Reserved. 87990cbe856818d5eddac44c7b1cdeb8
:no_upscale()/cdn.vox-cdn.com/uploads/chorus_image/image/72937824/1741788542.0.jpg)
